{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:57:20Z","timestamp":1792519040725,"version":"4.5.0"},"reference-count":118,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T00:00:00Z","timestamp":1657411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Systemic sclerosis is a chronic multisystem autoimmune disease, characterized by diffuse fibrosis and abnormalities of microcirculation and small arterioles in the skin, joints and visceral organs. Material and Methods: We searched for the relevant articles on systemic sclerosis and kidney involvement in systemic sclerosis in the NIH library of medicine, transplant, rheumatologic and nephrological journals. Results: Half of patients with systemic sclerosis have clinical evidence of kidney involvement. Scleroderma renal crisis represents the most specific and serious renal event associated with this condition. It is characterized by an abrupt onset of moderate to marked hypertension and kidney failure. Early and aggressive treatment is mandatory to prevent irreversible organ damage and death. The advent of ACE-inhibitors revolutionized the management of scleroderma renal crisis. However, the outcomes of this serious complication are still poor, and between 20 to 50% of patients progress to end stage renal disease. Conclusions: Scleroderma renal crisis still represents a serious and life-threatening event. Thus, further studies on its prevention and on new therapeutic strategies should be encouraged.<\/jats:p>","DOI":"10.3390\/jpm12071123","type":"journal-article","created":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T22:48:00Z","timestamp":1657493280000},"page":"1123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Kidney Involvement in Systemic Sclerosis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-618X","authenticated-orcid":false,"given":"Francesco","family":"Reggiani","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moroni","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6060-965X","authenticated-orcid":false,"given":"Claudio","family":"Ponticelli","sequence":"additional","affiliation":[{"name":"Independent Investigator, 20131 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"A311","DOI":"10.1016\/j.autrev.2009.11.003","article-title":"Geoepidemiology of systemic sclerosis","volume":"9","author":"Ranque","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CLEP.S191418","article-title":"Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease","volume":"11","author":"Bergamasco","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0889-857X(03)00022-X","article-title":"Scleroderma epidemiology","volume":"29","author":"Mayes","year":"2003","journal-title":"Rheum. Dis. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.180818","article-title":"Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis","volume":"46","author":"Pauling","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/14397595.2019.1702238","article-title":"Effect of season on clinical outcomes of Thai systemic sclerosis: Analysis of the Thai national healthcare database","volume":"30","author":"Foocharoen","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients with Systemic Sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2017.05.004","article-title":"Unfolding the pathogenesis of scleroderma through genomics and epigenomics","volume":"83","author":"Tsou","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/BOR.0000000000000735","article-title":"Systemic sclerosis pathogenesis: Contribution of recent advances in genetics","volume":"32","author":"Orvain","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3389\/fimmu.2018.02191","article-title":"Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin","volume":"9","author":"Apostolidis","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10067-016-3533-1","article-title":"Occupational and environmental scleroderma. Systematic review and meta-analysis","volume":"36","author":"Moreno","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7861\/clinmedicine.16-1-55","article-title":"Advances in pathogenesis and treatment of systemic sclerosis","volume":"16","author":"Denton","year":"2016","journal-title":"Clin. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11926-012-0297-8","article-title":"The Immune Pathogenesis of Scleroderma: Context Is Everything","volume":"15","author":"Greenblatt","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cvr\/cvu062","article-title":"Crosstalk between fibroblasts and inflammatory cells","volume":"102","author":"Miteva","year":"2014","journal-title":"Cardiovasc. Res"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/ni1004-971","article-title":"The interface between innate and adaptive immunity","volume":"5","author":"Hoebe","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/03009742.2010.528021","article-title":"Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis","volume":"40","author":"Papp","year":"2011","journal-title":"Scand. J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/annrheumdis-2011-200709","article-title":"Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions","volume":"71","author":"Mathian","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: Determined by skin subtype or auto-antibody subtype? A long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.41403","article-title":"Association of Anti\u2013Topoisomerase I Antibodies of the IgM Isotype with Disease Progression in Anti\u2013Topoisomerase I\u2013Positive Systemic Sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2015.00167","article-title":"Autoantibodies in systemic sclerosis: Unanswered questions","volume":"6","author":"Kayser","year":"2015","journal-title":"Front. Immunol"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12026-017-8926-y","article-title":"Pathogenesis of systemic sclerosis\u2014current concept and emerging treatments","volume":"65","author":"Furue","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front. Immunol"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.4049\/jimmunol.0903188","article-title":"HLA-B35 Upregulates Endothelin-1 and Downregulates Endothelial Nitric Oxide Synthase via Endoplasmic Reticulum Stress Response in Endothelial Cells","volume":"184","author":"Lenna","year":"2010","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/qjmed\/hct111","article-title":"Targeting the endothelin axis in scleroderma renal crisis: Rationale and feasibility","volume":"106","author":"Penn","year":"2013","journal-title":"QJM Int. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2249.2003.02320.x","article-title":"Serum nitric oxide (NO) levels in systemic sclerosis patients: Correlation between NO levels and clinical features","volume":"134","author":"Takagi","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1525619","DOI":"10.1155\/2021\/1525619","article-title":"Hypoxia Upregulates NOTCH3 Signaling Pathway to Promote Endothelial-Mesenchymal Transition in Pulmonary Artery Endothelial Cells","volume":"2021","author":"Wang","year":"2021","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2362.2009.02117.x","article-title":"Endothelin receptor selectivity: Evidence from in vitro and pre-clinical models of scleroderma","volume":"39","author":"Shiwen","year":"2009","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1038\/s41467-021-24601-y","article-title":"TGF\u03b2 promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy","volume":"12","author":"Zehender","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/BOR.0b013e3282eeb3a4","article-title":"Platelet contributions to the pathogenesis of systemic sclerosis","volume":"19","author":"Postlethwaite","year":"2007","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Paolini, C., Agarbati, S., Benfaremo, D., Mozzicafreddo, M., Svegliati, S., and Moroncini, G. (2022). PDGF\/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073904"},{"key":"ref_33","first-page":"75","article-title":"Agonistic anti-PDGF receptor autoantibodies from patients with systemic sclerosis impact human pulmonary artery smooth muscle cells function in vitro","volume":"8","author":"Svegliati","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.39728","article-title":"Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti\u2212Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies","volume":"68","author":"Luchetti","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.rdc.2015.04.002","article-title":"The pathogenesis of systemic sclerosis","volume":"41","author":"Stern","year":"2015","journal-title":"Rheum. Dis. Clin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00005792-198311000-00001","article-title":"Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases","volume":"62","author":"Traub","year":"1983","journal-title":"Medicine"},{"key":"ref_37","unstructured":"Shapiro, A.P., Medsger, T.A., and Steen, V.D. (1988). Renal involvement in systemic sclerosis. Diseases of Kidney, Little, Brown. [4th ed.]."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.autrev.2017.07.018","article-title":"How I treat patients with systemic sclerosis in clinical practice","volume":"16","author":"Rossi","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00296-021-04855-x","article-title":"Renal dysfunction in systemic sclerosis beyond scleroderma renal crisis","volume":"41","author":"Iliopoulos","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1053\/j.ajkd.2016.02.033","article-title":"AJKD Atlas of Renal Pathology: Systemic Sclerosis","volume":"67","author":"Lusco","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"538589","DOI":"10.1155\/2010\/538589","article-title":"Renal Manifestations in Scleroderma: Evidence for Subclinical Renal Disease as a Marker of Vasculopathy","volume":"2010","author":"Shanmugam","year":"2010","journal-title":"Int. J. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-005-0011-5","article-title":"Scleroderma associated with ANCA-associated vasculitis","volume":"26","author":"Rho","year":"2006","journal-title":"Rheumatol. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5414\/CN109445","article-title":"ANCA-associated vasculitis in scleroderma: A renal perspective","volume":"90","author":"Kant","year":"2018","journal-title":"Clin. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1093\/rheumatology\/keab278","article-title":"ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: A devastating combination of pathologies","volume":"60","author":"Hughes","year":"2021","journal-title":"Rheumatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1398-9995.1986.tb00326.x","article-title":"Antinuclear Antibodies and Anti-DNA Antibodies in Scleroderma","volume":"41","author":"Serup","year":"1986","journal-title":"Allergy"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-1839-5","article-title":"Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis","volume":"21","author":"Moxey","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.semarthrit.2014.12.001","article-title":"Scleroderma renal crisis","volume":"Volume 44","author":"Bose","year":"2015","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.2006.066985","article-title":"Mortality and risk factors of scleroderma renal crisis: A French retrospective study of 50 patients","volume":"67","author":"Teixeira","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: Patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM Int. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/anr.1780320911","article-title":"Normotensive renal failure in systemic sclerosis","volume":"32","author":"Helfrich","year":"1989","journal-title":"Arthritis Rheum. Off. J. Am. Coll. Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","article-title":"Scleroderma renal crisis: A retrospective multicentre study on 91 patients and 427 controls","volume":"51","author":"Guillevin","year":"2012","journal-title":"Rheumatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5114\/reum.2020.96655","article-title":"Haematological abnormalities in systemic sclerosis","volume":"58","author":"Wielosz","year":"2020","journal-title":"Reumatologia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3899\/jrheum.171186","article-title":"Risk Factors for Future Scleroderma Renal Crisis at Systemic Sclerosis Diagnosis","volume":"46","author":"Gordon","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","article-title":"Skin thickness progression rate: A predictor of mortality and early internal organ involvement in diffuse scleroderma","volume":"70","author":"Domsic","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/03009742.2011.610032","article-title":"Scleroderma renal crisis in a Swedish systemic sclerosis cohort: Survival, renal outcome, and RNA polymerase III antibodies as a risk factor","volume":"41","author":"Hesselstrand","year":"2012","journal-title":"Scand. J. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.3899\/jrheum.080806","article-title":"Serologic Profile and Mortality Rates of Scleroderma Renal Crisis in Italy","volume":"36","author":"Codullo","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum. Off. J. Am. Coll. Rheumatol."},{"key":"ref_59","first-page":"83","article-title":"Normotensive scleroderma renal crisis in a patient with progressive systemic sclerosis: Case report and review of literature","volume":"75","author":"Saeed","year":"2011","journal-title":"Connect. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kong, W., Wang, Y., Wang, H., Zhou, Q., Chen, J., and Han, F. (2022). Systemic sclerosis complicated with renal thrombotic microangiopathy: A case report and literature review. BMC Nephrol., 23.","DOI":"10.1186\/s12882-021-02639-w"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s100670050132","article-title":"Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis","volume":"18","author":"Kobayashi","year":"1999","journal-title":"Clin. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.humpath.2010.05.018","article-title":"Endothelin-1 expression in scleroderma renal crisis","volume":"42","author":"Mouthon","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bjp.0706412","article-title":"ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin","volume":"146","author":"Inscho","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1196\/annals.1351.002","article-title":"Angiotensin-Converting Enzyme in Systemic Sclerosis: From Endothelial Injury to a Genetic Polymorphism","volume":"1069","author":"Guiducci","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"543704","DOI":"10.1155\/2010\/543704","article-title":"Scleroderma Renal Crisis: A Pathology Perspective","volume":"2010","author":"Batal","year":"2010","journal-title":"Int. J. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.humpath.2008.08.001","article-title":"Renal biopsy findings predicting outcome in scleroderma renal crisis","volume":"40","author":"Batal","year":"2009","journal-title":"Hum. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.rdc.2015.04.008","article-title":"Scleroderma renal crisis","volume":"41","author":"Guillevin","year":"2015","journal-title":"Rheum. Dis. Clin."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s10157-017-1398-5","article-title":"The clinical and pathological characteristics of nephropathies in connective tissue diseases in the Japan Renal Biopsy Registry (J-RBR)","volume":"21","author":"Ichikawa","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1711660307","article-title":"Sequential dermal microvascular and perivascular changes in the development of scleroderma","volume":"166","author":"Prescott","year":"1992","journal-title":"J. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3899\/jrheum.170953","article-title":"Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome","volume":"45","author":"Alharbi","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/IJGM.S221471","article-title":"Renal pathology and clinical associations in systemic sclerosis: A historical cohort study","volume":"12","author":"Tonsawan","year":"2019","journal-title":"Int. J. Gen. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semarthrit.2010.11.001","article-title":"Anti-Neutrophil Antibody Associated Vasculitis in Systemic Sclerosis","volume":"41","author":"Arad","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","article-title":"Long-term outcomes of scleroderma renal crisis","volume":"133","author":"Steen","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1093\/ndt\/gfs317","article-title":"Prognosis of scleroderma renal crisis: A long-term observational study","volume":"27","author":"Cozzi","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40620-020-00746-9","article-title":"Systemic sclerosis and end-stage renal disease: Study of patient characteristics, follow-up and outcomes in France","volume":"34","author":"Lavergne","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1046\/j.1445-5994.2003.00358.x","article-title":"Scleroderma renal crisis: Poor outcome despite aggressive antihypertensive treatment","volume":"33","author":"Walker","year":"2003","journal-title":"Intern. Med. J."},{"key":"ref_77","first-page":"1","article-title":"Acute Heart Failure in Scleroderma Renal Crisis: A Case Study for Review of Cardiac Disease in Systemic Sclerosis","volume":"8","author":"Amarnani","year":"2020","journal-title":"Am. J. Med. Case Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000711","article-title":"Management of systemic sclerosis: The first five years","volume":"32","author":"Roofeh","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00296-016-3636-7","article-title":"Interstitial lung disease in systemic sclerosis: Current and future treatment","volume":"37","author":"Giacomelli","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1513\/AnnalsATS.201606-426FR","article-title":"Treatment of systemic Sclerosis\u2013related interstitial lung disease: A review of existing and emerging therapies","volume":"13","author":"Volkmann","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"Demarco","year":"2002","journal-title":"Arthritis Care Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10067-013-2422-0","article-title":"Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): A systematic review and meta-analysis of cohort studies and registries","volume":"33","author":"Iudici","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_83","first-page":"135","article-title":"Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series","volume":"31","author":"Montanelli","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: A prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_85","first-page":"1739","article-title":"A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study","volume":"19","author":"Rezus","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Castellv\u00ed, I., Sime\u00f3n, C.P., Sarmiento, M., Casademont, J., Corominas, H., and Fonollosa, V. (2020). Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0243651"},{"key":"ref_87","first-page":"151","article-title":"Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: A randomised, double-blind, placebo-controlled study","volume":"35","author":"Andrigueti","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-\u03b2 and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/1744666X.2020.1813569","article-title":"Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis","volume":"16","author":"Liakouli","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.2500\/ajra.2016.30.4389","article-title":"Rapamycin Inhibits Transforming Growth Factor Beta 1 Induced Myofibroblast Differentiation via the Phosphorylated-Phosphatidylinositol 3-Kinase Mammalian Target of Rapamycin Signal Pathways in Nasal Polyp\u2013Derived Fibroblasts","volume":"30","author":"Ko","year":"2016","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/art.24986","article-title":"Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study","volume":"60","author":"Su","year":"2009","journal-title":"Arthritis Rheum. Off. J. Am. Coll. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Fransen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13075-020-2141-2","article-title":"ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis\u2014A EUSTAR analysis","volume":"22","author":"Varisco","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Gordon, S.M., Hughes, J.B., Nee, R., Stitt, R.S., Bailey, W.T., Little, D.J., Edison, J.D., and Olson, S.W. (2019). Systemic sclerosis medications and risk of scleroderma renal crisis. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1467-y"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/jch.13026","article-title":"Blood pressure management and guideline adherence in hypertensive emergencies and urgencies: A comparison between telemedically supported and conventional out-of-hospital care","volume":"19","author":"Brokmann","year":"2017","journal-title":"J. Clin. Hypertens."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajh\/hpx048","article-title":"Trends in Hospitalization for Hypertensive Emergency, and Relationship of End-Organ Damage with In-Hospital Mortality","volume":"30","author":"Shah","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"ref_98","first-page":"39","article-title":"Malignant hypertension: A preventable emergency","volume":"126","year":"2013","journal-title":"NZ Med. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0025-6196(12)60418-2","article-title":"Use of captopril as early therapy for renal scleroderma: A prospective study","volume":"Volume 60","author":"Beckett","year":"1985","journal-title":"Mayo Clinic Proceedings"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrneph.2016.124","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"12","author":"Woodworth","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.autrev.2018.03.012","article-title":"Therapy of scleroderma renal crisis: State of the art","volume":"17","author":"Zanatta","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/j.ajkd.2005.01.007","article-title":"Late Recurrence of Scleroderma Renal Crisis in a Renal Transplant Recipient Despite Angiotensin II Blockade","volume":"45","author":"Cheung","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_104","first-page":"293","article-title":"Reversible acute renal faiure in diffuse scleroderma","volume":"13","author":"Ponticelli","year":"1980","journal-title":"Clin. Nephrol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1081\/JDI-100107372","article-title":"Thrombotic thrombocytopenic purpura in a case of scleroderma renal crisis treated with twice-daily therapeutic plasma exchange","volume":"23","author":"Mahfouz","year":"2001","journal-title":"Ren. Fail."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2169\/internalmedicine.1441-18","article-title":"Scleroderma Renal Crisis Complicated with Thrombotic Microangiopathy Triggered by Influenza B Virus Infection","volume":"58","author":"Shimizu","year":"2019","journal-title":"Intern. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/ckj\/sfw143","article-title":"Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: Three cases treated with eculizumab","volume":"10","author":"Allinovi","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40620-016-0357-7","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: Case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J. Nephrol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/187152811794352088","article-title":"Endothelin receptor antagonists as disease modifiers in systemic sclerosis","volume":"10","author":"Shetty","year":"2011","journal-title":"Inflamm. Allergy-Drug Targets."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/BOR.0000000000000604","article-title":"Management of scleroderma renal crisis","volume":"31","author":"Nagaraja","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/ndt\/gfq861","article-title":"End-stage kidney disease due to scleroderma\u2014Outcomes in 127 consecutive ANZDATA registry cases","volume":"26","author":"Siva","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ekir.2017.09.003","article-title":"End-Stage Kidney Disease From Scleroderma in the United States, 1996 to 2012","volume":"3","author":"Sexton","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.ajkd.2018.05.016","article-title":"Characteristics and Outcomes of Patients with Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results from the ERA-EDTA Registry","volume":"73","author":"Hruskova","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5500\/wjt.v11.i9.372","article-title":"Journey of a patient with scleroderma from renal failure up to kidney transplantation","volume":"11","author":"Abbas","year":"2021","journal-title":"World J. Transplant."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1111\/j.1600-6143.2005.01035.x","article-title":"Predictors and Risk Factors for Recurrent Scleroderma Renal Crisis in the Kidney Allograft: Case Report and Review of the Literature","volume":"5","author":"Pham","year":"2005","journal-title":"Am. J. Transplant."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/j.1600-6143.2004.00605.x","article-title":"Kidney Transplantation for Systemic Sclerosis Improves Survival and may Modulate Disease Activity","volume":"4","author":"Gibney","year":"2004","journal-title":"Am. J. Transplant."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/tri.12923","article-title":"Kidney transplantation in patients with systemic sclerosis: A nationwide multicentre study","volume":"30","author":"Bertrand","year":"2017","journal-title":"Transpl. Int."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/7\/1123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:47:38Z","timestamp":1760140058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/7\/1123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,10]]},"references-count":118,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jpm12071123"],"URL":"https:\/\/doi.org\/10.3390\/jpm12071123","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,10]]}}}